167 related articles for article (PubMed ID: 34656761)
21. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma.
Zhou M; Chen Y; Gong Y; Zhu M; Cen J; Pan J; Yan L; Shang J; Jin S; Shi X; Yao W; Yan S; Wu D; Chen S; Fu C; Yao L
Discov Oncol; 2024 Mar; 15(1):78. PubMed ID: 38502423
[TBL] [Abstract][Full Text] [Related]
22. Improvement of clonality detection rate in multiple myeloma using fluorescent IgH PCR with different sets of primers.
Welterlin V; Debecker A; Tschieb D; Zanetti C; Lange W; Hénon PR
J Hematother Stem Cell Res; 2000 Dec; 9(6):983-91. PubMed ID: 11177613
[TBL] [Abstract][Full Text] [Related]
23. Clinical implication of minimal residual disease assessment by next-generation sequencing-based immunoglobulin clonality assay in pediatric B-acute lymphoblastic leukemia.
Lee JW; Kim Y; Ahn A; Lee JM; Yoo JW; Kim S; Cho B; Chung NG; Kim M
Front Oncol; 2022; 12():957743. PubMed ID: 36185293
[TBL] [Abstract][Full Text] [Related]
24. Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.
Hultcrantz M; Rustad EH; Yellapantula V; Jacob A; Akhlaghi T; Korde N; Mailankody S; Lesokhin AM; Hassoun H; Smith EL; Lahoud OB; Landau HJ; Shah GL; Scordo M; Chung DJ; Giralt S; Papaemmanuil E; Landgren O
Clin Cancer Res; 2022 May; 28(10):2160-2166. PubMed ID: 35553646
[TBL] [Abstract][Full Text] [Related]
25. Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms.
Arcila ME; Yu W; Syed M; Kim H; Maciag L; Yao J; Ho C; Petrova K; Moung C; Salazar P; Rijo I; Baldi T; Zehir A; Landgren O; Park J; Roshal M; Dogan A; Nafa K
J Mol Diagn; 2019 Mar; 21(2):330-342. PubMed ID: 30590126
[TBL] [Abstract][Full Text] [Related]
26. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
27. Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes-A feasibility study.
Marx A; Osváth M; Szikora B; Pipek O; Csabai I; Nagy Á; Bödör C; Matula Z; Nagy G; Bors A; Uher F; Mikala G; Vályi-Nagy I; Kacskovics I
PLoS One; 2023; 18(5):e0285696. PubMed ID: 37235573
[TBL] [Abstract][Full Text] [Related]
28. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
29. Multiple Immunoglobulin κ Gene Rearrangements within a Single Clone Unraveled by Next-Generation Sequencing-Based Clonality Assessment.
Leenders AM; Kroeze LI; Rijntjes J; Luijks J; Hebeda KM; Darzentas N; Langerak AW; van den Brand M; Groenen PJTA
J Mol Diagn; 2021 Sep; 23(9):1097-1104. PubMed ID: 34020040
[TBL] [Abstract][Full Text] [Related]
30. EuroClonality-NGS Recommendations for Evaluation of B-Cell Clonality Analysis by Next-Generation Sequencing: A Structured Approach with the DEPART Algorithm.
van den Brand M; Möbs M; Otto F; Kroeze LI; Gonzalez de Castro D; Stamatopoulos K; Davi F; Bravetti C; Kolijn PM; Vlachonikola E; Stewart JP; Pott C; Hummel M; Darzentas N; Langerak AW; Fend F; Groenen PJTA
J Mol Diagn; 2023 Oct; 25(10):729-739. PubMed ID: 37467928
[TBL] [Abstract][Full Text] [Related]
31. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
[TBL] [Abstract][Full Text] [Related]
32. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.
van Dongen JJ; Langerak AW; Brüggemann M; Evans PA; Hummel M; Lavender FL; Delabesse E; Davi F; Schuuring E; García-Sanz R; van Krieken JH; Droese J; González D; Bastard C; White HE; Spaargaren M; González M; Parreira A; Smith JL; Morgan GJ; Kneba M; Macintyre EA
Leukemia; 2003 Dec; 17(12):2257-317. PubMed ID: 14671650
[TBL] [Abstract][Full Text] [Related]
33. [Significance of BIOMED-2 standardized IG/TCR gene rearrangement detection in paraffin-embedded section in lymphoma diagnosis].
Ai X; Fu Q; Wang J; Zheng Y; Han C; Li Q; Sun Q; Ru K
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):495-8. PubMed ID: 24985170
[TBL] [Abstract][Full Text] [Related]
34. Detection of clonal immunoglobulin and T-cell receptor gene recombination in hematological malignancies: monitoring minimal residual disease.
García-Castillo H; Barros-Núñez P
Cardiovasc Hematol Disord Drug Targets; 2009 Jun; 9(2):124-35. PubMed ID: 19519371
[TBL] [Abstract][Full Text] [Related]
35. Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing-Based Clonality Testing in B-Cell and Plasma Cell Neoplasms.
Liu Y; Ho C; Yu W; Huang Y; Miller J; Gao Q; Syed M; Ma Y; Wang M; Maciag L; Petrova-Drus K; Zhu M; Yao J; Vanderbilt C; Durham B; Benhamida J; Ewalt MD; Dogan A; Roshal M; Nafa K; Arcila ME
J Mol Diagn; 2024 Mar; 26(3):168-178. PubMed ID: 38103591
[TBL] [Abstract][Full Text] [Related]
36. Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators.
Van der Straeten J; De Brouwer W; Kabongo E; Dresse MF; Fostier K; Schots R; Van Riet I; Bakkus M
J Mol Diagn; 2021 May; 23(5):599-611. PubMed ID: 33549860
[TBL] [Abstract][Full Text] [Related]
37. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
[TBL] [Abstract][Full Text] [Related]
38. Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies.
Hussaini MO; Srivastava J; Lee LW; Nishihori T; Shah BD; Alsina M; Pinilla-Ibarz J; Shain KH
Arch Pathol Lab Med; 2022 Apr; 146(4):485-493. PubMed ID: 34343238
[TBL] [Abstract][Full Text] [Related]
39. Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
Genuardi E; Romano G; Beccuti M; Alessandria B; Mannina D; Califano C; Rota Scalabrini D; Cortelazzo S; Ladetto M; Ferrero S; Calogero RA; Cordero F
Br J Haematol; 2021 Jul; 194(2):378-381. PubMed ID: 34002365
[TBL] [Abstract][Full Text] [Related]
40. [Prognostic value of minimal residual disease detection in multiple myeloma].
Takamatsu H
Nihon Rinsho; 2015 Jan; 73(1):69-73. PubMed ID: 25626307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
